JP2008534603A - １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル - Google Patents
１日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル Download PDFInfo
- Publication number
- JP2008534603A JP2008534603A JP2008504316A JP2008504316A JP2008534603A JP 2008534603 A JP2008534603 A JP 2008534603A JP 2008504316 A JP2008504316 A JP 2008504316A JP 2008504316 A JP2008504316 A JP 2008504316A JP 2008534603 A JP2008534603 A JP 2008534603A
- Authority
- JP
- Japan
- Prior art keywords
- treatment
- famciclovir
- lesions
- lesion
- day
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 63
- 208000004898 Herpes Labialis Diseases 0.000 title claims abstract description 36
- GGXKWVWZWMLJEH-UHFFFAOYSA-N famcyclovir Chemical compound N1=C(N)N=C2N(CCC(COC(=O)C)COC(C)=O)C=NC2=C1 GGXKWVWZWMLJEH-UHFFFAOYSA-N 0.000 title claims abstract description 34
- 229960004396 famciclovir Drugs 0.000 title claims abstract description 33
- 230000000306 recurrent effect Effects 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims description 24
- 208000037048 Prodromal Symptoms Diseases 0.000 claims description 9
- JNTOCHDNEULJHD-UHFFFAOYSA-N Penciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(CCC(CO)CO)C=N2 JNTOCHDNEULJHD-UHFFFAOYSA-N 0.000 abstract description 8
- 229960001179 penciclovir Drugs 0.000 abstract description 7
- 241000124008 Mammalia Species 0.000 abstract 2
- 230000003902 lesion Effects 0.000 description 83
- 230000035876 healing Effects 0.000 description 45
- 239000000902 placebo Substances 0.000 description 30
- 229940068196 placebo Drugs 0.000 description 30
- 206010039509 Scab Diseases 0.000 description 17
- 206010067152 Oral herpes Diseases 0.000 description 16
- 230000002354 daily effect Effects 0.000 description 13
- 230000009290 primary effect Effects 0.000 description 13
- 208000025865 Ulcer Diseases 0.000 description 12
- 231100000397 ulcer Toxicity 0.000 description 11
- 230000008034 disappearance Effects 0.000 description 10
- 238000012360 testing method Methods 0.000 description 10
- 206010015150 Erythema Diseases 0.000 description 9
- 208000002193 Pain Diseases 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 231100000321 erythema Toxicity 0.000 description 8
- 239000002243 precursor Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 238000011269 treatment regimen Methods 0.000 description 7
- 125000002252 acyl group Chemical group 0.000 description 6
- 208000002352 blister Diseases 0.000 description 6
- 238000009826 distribution Methods 0.000 description 6
- 229940104320 famciclovir 750 mg Drugs 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000002250 progressing effect Effects 0.000 description 6
- 230000009291 secondary effect Effects 0.000 description 6
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 4
- 229960004150 aciclovir Drugs 0.000 description 4
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 206010012441 Dermatitis bullous Diseases 0.000 description 3
- 229910019142 PO4 Inorganic materials 0.000 description 3
- 206010033733 Papule Diseases 0.000 description 3
- 230000002411 adverse Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000037311 normal skin Effects 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- -1 phosphate ester Chemical class 0.000 description 3
- 238000004904 shortening Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- HDOVUKNUBWVHOX-QMMMGPOBSA-N Valacyclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCOC(=O)[C@@H](N)C(C)C)C=N2 HDOVUKNUBWVHOX-QMMMGPOBSA-N 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940002612 prodrug Drugs 0.000 description 2
- 239000000651 prodrug Substances 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- BRPTUOYNOCSFRJ-FYZOBXCZSA-N sodium (2S)-4-(2-amino-6-oxo-1H-purin-9-yl)-2-(hydroxymethyl)butan-1-olate Chemical class [Na+].Nc1nc(=O)c2ncn(CC[C@H](CO)C[O-])c2[nH]1 BRPTUOYNOCSFRJ-FYZOBXCZSA-N 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 229940093257 valacyclovir Drugs 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010053262 Skin swelling Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000001133 acceleration Effects 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009513 drug distribution Methods 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 229940097919 famciclovir 500 mg Drugs 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000001325 log-rank test Methods 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66653605P | 2005-03-30 | 2005-03-30 | |
| PCT/US2006/011498 WO2006105216A1 (en) | 2005-03-30 | 2006-03-29 | Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012232172A Division JP6018473B2 (ja) | 2005-03-30 | 2012-10-19 | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2008534603A true JP2008534603A (ja) | 2008-08-28 |
Family
ID=36829888
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008504316A Withdrawn JP2008534603A (ja) | 2005-03-30 | 2006-03-29 | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル |
| JP2012232172A Expired - Fee Related JP6018473B2 (ja) | 2005-03-30 | 2012-10-19 | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル |
| JP2015075416A Withdrawn JP2015163614A (ja) | 2005-03-30 | 2015-04-01 | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012232172A Expired - Fee Related JP6018473B2 (ja) | 2005-03-30 | 2012-10-19 | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル |
| JP2015075416A Withdrawn JP2015163614A (ja) | 2005-03-30 | 2015-04-01 | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20100298353A1 (enExample) |
| EP (2) | EP2363131A1 (enExample) |
| JP (3) | JP2008534603A (enExample) |
| KR (1) | KR101312820B1 (enExample) |
| CN (1) | CN101678028A (enExample) |
| AT (1) | ATE545419T1 (enExample) |
| AU (3) | AU2006230269A1 (enExample) |
| BR (1) | BRPI0609793A2 (enExample) |
| CA (1) | CA2602641A1 (enExample) |
| ES (1) | ES2382664T3 (enExample) |
| PL (1) | PL1865961T3 (enExample) |
| PT (1) | PT1865961E (enExample) |
| RU (2) | RU2007139762A (enExample) |
| TW (1) | TW200716124A (enExample) |
| WO (1) | WO2006105194A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006230269A1 (en) * | 2005-03-30 | 2006-10-05 | Novartis Ag | Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3485225D1 (de) | 1983-08-18 | 1991-12-05 | Beecham Group Plc | Antivirale guanin-derivate. |
| DE3582399D1 (de) | 1984-09-20 | 1991-05-08 | Beecham Group Plc | Purin-derivate und ihre pharmazeutische verwendung. |
| DE3671227D1 (de) | 1985-07-27 | 1990-06-21 | Beecham Group Plc | 9-substituierte guaninmonohydrate. |
| GB8628826D0 (en) | 1986-12-02 | 1987-01-07 | Beecham Group Plc | Pharmaceutical products |
| US5840763A (en) * | 1994-12-12 | 1998-11-24 | Smithkline Beecham Plc | Treatment of a latent infection of herpes viruses |
| RU2179849C2 (ru) * | 1999-07-27 | 2002-02-27 | Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии | Способ лечения рецидивирующего генитального герпеса у женщин |
| RU2178699C1 (ru) * | 2001-04-04 | 2002-01-27 | Змызгова Анна Васильевна | Способ лечения герпесовирусных инфекций, включающий озонотерапию |
| AU2006230269A1 (en) * | 2005-03-30 | 2006-10-05 | Novartis Ag | Penciclovir or famciclovir for the treatment of recurrent genital herpes with a one-day application |
-
2006
- 2006-03-28 AU AU2006230269A patent/AU2006230269A1/en not_active Abandoned
- 2006-03-29 EP EP10179668A patent/EP2363131A1/en not_active Withdrawn
- 2006-03-29 EP EP06739956A patent/EP1865961B1/en active Active
- 2006-03-29 RU RU2007139762/14A patent/RU2007139762A/ru unknown
- 2006-03-29 PL PL06739956T patent/PL1865961T3/pl unknown
- 2006-03-29 KR KR1020077024918A patent/KR101312820B1/ko not_active Expired - Fee Related
- 2006-03-29 ES ES06739956T patent/ES2382664T3/es active Active
- 2006-03-29 WO PCT/US2006/011460 patent/WO2006105194A2/en not_active Ceased
- 2006-03-29 JP JP2008504316A patent/JP2008534603A/ja not_active Withdrawn
- 2006-03-29 PT PT06739956T patent/PT1865961E/pt unknown
- 2006-03-29 TW TW095110943A patent/TW200716124A/zh unknown
- 2006-03-29 RU RU2007139758/15A patent/RU2432951C2/ru active
- 2006-03-29 CA CA002602641A patent/CA2602641A1/en not_active Abandoned
- 2006-03-29 AT AT06739956T patent/ATE545419T1/de active
- 2006-03-29 AU AU2006230291A patent/AU2006230291A1/en not_active Abandoned
- 2006-03-29 BR BRPI0609793-6A patent/BRPI0609793A2/pt not_active IP Right Cessation
- 2006-03-29 CN CN200680010840A patent/CN101678028A/zh active Pending
-
2010
- 2010-05-06 AU AU2010201834A patent/AU2010201834B2/en not_active Expired - Fee Related
- 2010-07-01 US US12/803,649 patent/US20100298353A1/en not_active Abandoned
-
2011
- 2011-12-20 US US13/330,979 patent/US20120088781A1/en not_active Abandoned
-
2012
- 2012-09-06 US US13/604,955 patent/US20120329814A1/en not_active Abandoned
- 2012-10-19 JP JP2012232172A patent/JP6018473B2/ja not_active Expired - Fee Related
-
2014
- 2014-04-14 US US14/252,514 patent/US20150005324A1/en not_active Abandoned
-
2015
- 2015-04-01 JP JP2015075416A patent/JP2015163614A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010201834A1 (en) | 2010-05-27 |
| US20100298353A1 (en) | 2010-11-25 |
| US20120329814A1 (en) | 2012-12-27 |
| JP2013049687A (ja) | 2013-03-14 |
| KR101312820B1 (ko) | 2013-09-27 |
| KR20080004535A (ko) | 2008-01-09 |
| ATE545419T1 (de) | 2012-03-15 |
| RU2007139762A (ru) | 2009-05-10 |
| AU2006230291A8 (en) | 2013-10-24 |
| PL1865961T3 (pl) | 2012-07-31 |
| WO2006105194A2 (en) | 2006-10-05 |
| EP2363131A1 (en) | 2011-09-07 |
| EP1865961B1 (en) | 2012-02-15 |
| RU2007139758A (ru) | 2009-05-10 |
| WO2006105194A3 (en) | 2006-12-21 |
| RU2432951C2 (ru) | 2011-11-10 |
| BRPI0609793A2 (pt) | 2010-04-27 |
| JP2015163614A (ja) | 2015-09-10 |
| AU2006230269A1 (en) | 2006-10-05 |
| US20150005324A1 (en) | 2015-01-01 |
| AU2006230291A1 (en) | 2006-10-05 |
| TW200716124A (en) | 2007-05-01 |
| PT1865961E (pt) | 2012-05-22 |
| CA2602641A1 (en) | 2006-10-05 |
| ES2382664T3 (es) | 2012-06-12 |
| JP6018473B2 (ja) | 2016-11-02 |
| CN101678028A (zh) | 2010-03-24 |
| US20120088781A1 (en) | 2012-04-12 |
| AU2010201834B2 (en) | 2012-04-19 |
| EP1865961A1 (en) | 2007-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodriguez et al. | Efficacy and safety of aerosolized ribavirin in young children hospitalized with influenza: a double-blind, multicenter, placebo-controlled trial | |
| JP6018473B2 (ja) | １日１回処置を使用する再発性口唇ヘルペスの処置のためのファムシクロビル | |
| US6124304A (en) | Penciclovir for the treatment of zoster associated pain | |
| JP3768527B2 (ja) | 治療後の神経痛の治療のためのペンシクロリンの使用 | |
| AU2010201836C1 (en) | Famciclovir for the treatment of recurrent herpes labialis using a one-day treatment | |
| US20110245277A1 (en) | Famciclovir for the Treatment of Recurrent Herpes Labialis Using a One-Day Treatment | |
| TWI418347B (zh) | 治療疱疹病毒感染的方法 | |
| WO2021207386A1 (en) | Methods, compositions, and dosing regimens for treatment of sars-cov-2 infections | |
| KR20080004536A (ko) | 1-일 적용으로 재발성 음부 헤르페스를 치료하기 위한펜시클로버 또는 팜시클로버 | |
| JPH09506883A (ja) | 薬 剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090312 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120420 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120619 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20140911 |